

LETTER

Open Access

# Clinical determinants for fatality of 44,672 patients with COVID-19



Guangtong Deng<sup>1,2,3,4</sup>, Mingzhu Yin<sup>1,2,3,4</sup>, Xiang Chen<sup>1,2,3,4</sup> and Furong Zeng<sup>1,2,3,4\*</sup>

Using meta-analysis to explore clinical determinants for death of COVID-19 patients has been a problem due to insufficient sample size and overlapped cases [1]. In the study, we re-analyzed the largest confirmed case series reported publicly by the Chinese center for disease control and prevention (44,672 laboratory confirmed cases updated through February 11, 2020, [2]), to explore the clinical risk factors associated with death.

The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1. Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up. The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a). The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3]. Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89,  $p < 0.001$ ) (see Fig. 1b).

Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43,  $p < 0.001$ ), hypertension (HR = 4.48, 95%CI = 3.69–5.45,  $p < 0.001$ ), diabetes (RR = 4.43, 95%CI = 3.49–5.61,  $p < 0.001$ ), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87,  $p < 0.001$ ), and cancers (RR = 2.926, 95%CI = 1.34–6.41,  $p = 0.006$ ) were the risk factors for fatality of patients with COVID-19.

In summary, we found that there was no difference in the prevalence of COVID-19 between men and women, but male patients had a nearly 1.7-fold higher risk of death than female patients. Moreover, we concluded that patients with comorbidities had a significantly high death risk. Admittedly, due to the unavailability of individual patient data, we could not exclude the influence of age on the conclusion because old patients were more likely to have the underlying comorbidities. We would like to provide a reminder to the physicians that more intensive surveillance or treatment should be considered for male patients and those with comorbidities. Further and larger studies are needed to validate the findings.

\* Correspondence: [zengflorachn@hotmail.com](mailto:zengflorachn@hotmail.com)

<sup>1</sup>The Department of Dermatology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, China

<sup>2</sup>Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China

Full list of author information is available at the end of the article




© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Table 1** Characteristics between survivors and non-survivors with COVID-19

Characteristics	Total (n = 44,672)	Non-survivors (n = 1023)	Survivors (n = 43,649)	Fatality (%)	RR (95%CI)	p
<b>Age, n (%)</b>						
0–	416 (0.9%)	0	416 (0.9%)	0		
10–	549 (1.2%)	1 (0.1%)	548 (1.3%)	0.2		
20–	3619 (8.1%)	7 (0.7%)	3612 (8.3%)	0.2		
30–	7600 (17.0%)	18 (1.8%)	7582 (17.4%)	0.2		
40–	8571 (19.2%)	38 (3.7%)	8533 (19.5%)	0.4		
50–	10,008 (22.4%)	130 (12.7%)	9878 (22.6%)	1.3		
60–	8583 (19.2%)	309 (30.2%)	8274 (19.0%)	3.6		
70–	3918 (8.8%)	312 (30.5%)	3606 (8.3%)	8.0		
≥ 80	1408 (3.2%)	208 (20.3%)	1200 (2.7%)	14.8		
<b>Severity*, n (%)</b>						
Mild/moderate	36,160 (80.9%)	0	36,160 (82.8%)	0		
Severe	6168 (13.8%)	0	6168 (14.1%)	0		
Critical	2087 (4.7%)	1023 (100%)	1064 (2.4%)	49.0		
<b>Gender, n (%)</b>						
Male	22,981 (51.4%)	653 (63.8%)	22,328 (51.2%)	2.8	1.67 (1.47–1.89)	< 0.001
Female	21,691 (48.6%)	370 (36.2%)	21,321 (48.8%)	1.7		
<b>Comorbidity#, n (%)</b>						
Hypertension	2683 (12.8%)	161 (39.7%)	2522 (12.3%)	6.0	4.48 (3.69–5.45)	< 0.001
Diabetes	1102 (5.3%)	80 (19.7%)	1022 (5.0%)	7.3	4.47 (3.49–5.61)	< 0.001
Cardiovascular disease	873 (4.2%)	92 (22.7%)	781 (3.8%)	10.5	6.75 (5.40–8.43)	< 0.001
Respiratory disease	511 (2.4%)	32 (7.9%)	479 (2.3%)	6.3	3.43 (2.42–4.87)	< 0.001
Cancer	107 (0.5%)	6 (1.5%)	101 (0.5%)	5.6	2.93 (1.34–6.41)	0.006

\*Missing data (n = 257 in survivors group)

#Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group)



**Fig. 1** Fatality rate distribution of age (a) and gender (b). \*\*\* $p < 0.001$

**Acknowledgements**

None.

**Authors' contributions**

GD and FZ conceptualized the idea and designed the study. MY and XC revised the manuscript. The authors read and approved the final manuscript.

**Funding**

This work was supported by the grants from the National Natural Science Foundation of China (No. 81620108024).

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

All authors declare no competing interests.

**Author details**

<sup>1</sup>The Department of Dermatology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, China. <sup>2</sup>Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China. <sup>3</sup>Hunan Engineering Research Center of Skin Health and Disease, Changsha, China. <sup>4</sup>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.

Received: 26 March 2020 Accepted: 16 April 2020

Published online: 28 April 2020

**References**

1. Bauchner H, Golub RM, Zylke J. Editorial concern-possible reporting of the same patients with COVID-19 in different reports. *JAMA*. 2020. <https://doi.org/10.1001/jama.2020.3980>.
2. Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2020; 41(2):145–51.
3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020. <https://doi.org/10.1056/NEJMoa2002032>.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.